MENLO PARK, CA--(Marketwired - February 24, 2015) - 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that focus on the role of fatty acid synthase (FASN) in oncology and virology, announced today that it will present at the Cowen and Company 35th Annual Health Care Conference in Boston, MA. Merdad Parsey, Chief Executive Officer, is scheduled to present on Wednesday, March 4th at 11:30a.m. ET.
About 3-V Biosciences
3-V Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapeutics that focus on the role of fatty acid synthase (FASN) in oncology and virology. FASN is a well-credentialed target that plays a key role in lipogenesis with potential in several therapeutic areas including oncology, virology and metabolism. The company’s lead candidate is a first-in-class, oral FASN inhibitor in Phase 1 clinical development for oncology. 3-V also has an antiviral development candidate that has demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
For additional information on 3-V Biosciences, please visit www.3vbio.com.
Investor Relations Contact:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
Email Contact
Help employers find you! Check out all the jobs and post your resume.
